When one plus one makes three: The quest for rational antiepileptic polytherapy with supraadditive anticonvulsant efficacy

Epilepsy and Behavior

Volumn 27, Issue 3, 2013, Pages 439-442

  Brigo, Francesco ^a,b   Ausserer, Harald ^b   Tezzon, Frediano ^b   Nardone, Raffaele ^b,c  

^a UNIVERSITY OF VERONA   (Italy)

^b FRANZ TAPPEINER HOSPITAL   (Italy)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Antiepileptic drugs; Epilepsy; Rational polytherapy; Synergic effect; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; CLOBAZAM; ETHOSUXIMIDE; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; STIRIPENTOL; VALPROIC ACID;

DRUG EFFICACY; DRUG POTENTIATION; EPILEPSY; HUMAN; MYOCLONUS EPILEPSY; NEUROTOXICITY; REVIEW; SEIZURE;

ANTICONVULSANTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EPILEPSY; HUMANS; TREATMENT OUTCOME;

EID: 84876437933     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2013.03.010     Document Type: Review

References (30)

1. French J.A., Faught E. Rational polytherapy. Epilepsia 2009, 50(Suppl. 8):63-68.
2. St Louis E.K. Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Curr Neuropharmacol 2009, 7:96-105.
3. Brodie M.J., Sills G.J. Combining antiepileptic drugs-rational polytherapy?. Seizure 2011, 20:369-375.
4. Sander J.W.A.S. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993, 34:1007-1016.
5. Berenbaum M.C. What is synergy?. Pharmacol Rev 1989, 41:93-141.
6. Tallarida R.J. Statistical analysis of drug combinations for synergism. Pain 1992, 49:93-97.
7. Czuczwar S.J., Borowicz K.K. Polytherapy in epilepsy: the experimental evidence. Epilepsy Res 2002, 52:15-23.
8. Cereghino J.J., Brock J.T., Van Meter J.C., Penry J.K., Smith L.D., White B.G. The efficacy of carbamazepine combinations in epilepsy. Clin Pharmacol Ther 1975, 18:733-741.
9. Brodie M.J., Yuen A.W. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997, 26:423-432.
10. Besag F.M., Berry D.J., Pool F., Newbery J.E., Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?. Epilepsia 1998, 39:183-187.
11. Barcs G., Walker E.B., Elger C.E., et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000, 41:1597-1607.
12. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on?. Seizure 2000, 9:464-468.
13. Kwan P., Brodie M.J. Combination therapy in epilepsy: when and what to use. Drugs 2006, 66:1817-1829.
14. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006, 61:246-255.
15. White H.S., Smith M.D., Wilcox K.S. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 2007, 81:85-110.
16. Chaves J., Sander J.W. Seizure aggravation in idiopathic generalized epilepsies. Epilepsia 2005, 46(S9):133-139.
17. Rowan A.J., Meijer J.W., de Beer-Pawlikowski N., van der Geest P., Meinardi H. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983, 40:797-802.
18. Pisani F., Oteri G., Russo M.F., Di Perri R., Perucca E., Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999, 40:1141-1146.
19. Yuen A.W., Land G., Weatherley B.C., Peck A.W. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992, 33:511-513.
20. Reutens D.C., Duncan J.S., Patsalos P.N. Disabling tremor after lamotrigine with sodium valproate. Lancet 1993, 17(342):185-186.
21. Li L.M., Russo M., O'Donoghue M.F., Duncan J.S., Sander J.W. Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arq Neuropsiquiatr 1996, 54:47-49.
22. Wong I.C., Mawer G.E., Sander J.W. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999, 33:1037-1042.
23. Kanner A.M. When thinking of lamotrigine and valproic acid, think "pharmacokinetically"!. Epilepsy Curr 2004, 4:206-207.
24. Faught E., Morris G., Jacobson M., et al. Adding lamotrigine to valproate: incidence of rash and other adverse effects. Epilepsia 1999, 40:1135-1140.
25. Chung S., Ben-Menachem E., Sperling M.R., et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs 2010, 24:1041-1054.
26. Shandra A., Shandra P., Kaschenko O., Stoehr T. Eur J Neurol 2007, 14(Suppl. 1):211.
27. Stephen L.J., Brodie M.J. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs 2011, 25:89-107.
28. Striano S., Striano P., Capone D., Pisani F. Limited place for plasma monitoring of new antiepileptic drugs in clinical practice. Med Sci Monit 2008, 14:RA173-RA178.
29. Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat 2008, 4:507-523.
30. Chiron C. Stiripentol. Neurotherapeutics 2007, 4:123-125.